Navigation Links
Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc.
Date:11/17/2009

SEOUL, South Korea, Nov. 17 /PRNewswire/ -- Arigene Co., Ltd., a Korean corporation traded on the Korean Securities Dealers Association Quotation System ("Arigene") (KOSDAQ: 067850), today announced that it has entered into an amendment to its previously announced merger agreement dated October 2, 2009 with Trimeris, Inc. ("Trimeris") ( TRMS). The amendment provides for an extension of the expiration date of the tender offer being conducted by Arigene for Trimeris' outstanding common stock pursuant to the merger agreement and other adjustments pertaining to the agreement's termination and escrow provisions.

As of 5:00 p.m. Eastern time on November 16, 2009, 18,462,006 shares of Trimeris' common stock were tendered in the tender offer, representing 82.72% of the outstanding shares of Trimeris' common stock.

The tender offer was originally scheduled to expire at midnight, New York City time, on Monday, November 16, 2009. The amendment provides an extension of the expiration date for the tender offer through 5:00 pm, New York City time, on Monday, December 28, 2009. The amendment also provides an extension of the outside date, the date after which either party may terminate the merger agreement if Arigene's wholly-owned subsidiary, RTM Acquisition Company, has not accepted and paid for all shares validly tendered and not properly withdrawn prior to such time, to January 31, 2010.

Pursuant to the amendment, Arigene also agreed that certain conditions to Arigene's obligation to accept for payment and pay for any shares of Trimeris' common stock tendered pursuant to the tender offer have been satisfied as of 5:00 pm, New York City time on the date of the amendment and irrevocably waived compliance with such conditions at the close of the tender offer as extended thereby. The waived conditions include requirements that at the time of acceptance and payment for tendered shares of Trimeris' common stock that the representations and warranties of Trimeris are true and correct, that Trimeris has performed all covenants and obligations under the merger agreement and the delivery of a management certificate from Trimeris as to satisfaction of these conditions.

Pursuant to the terms of the amendment, the parties also concurrently executed a joint instruction letter to the escrow agent, providing the release of $12,000,000 of the escrow deposit to Trimeris in consideration for the amendment.

About Trimeris, Inc.

Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON®, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company's website at http://www.trimeris.com.

About Arigene Co., Ltd.

Arigene Co., Ltd. (KOSDAQ: 067850) is a developer, manufacturer and marketer of Ubiquitous Healthcare Systems (U-Healthcare) and related medical equipment in Korea. With its planned acquisition of Trimeris, Inc., Arigene is expanding its business to the broader biotechnology industry.

Cautionary Note regarding Forward Looking Statements

This document and any attachments may contain forward-looking information about the proposed transaction between Trimeris and Arigene, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined company, new product development, including obtaining regulatory approvals, and any other statements about Trimeris' managements' future expectations, beliefs, goals, plans or prospects constitute forward looking statements. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward looking statements. These forward looking statements involve known and unknown risks and uncertainties that may cause Trimeris' actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward looking statements. Important factors that may cause or contribute to such differences include uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Trimeris' stockholders will tender their stock in the offer; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, licensees, other business partners or governmental entities; transaction costs; whether results obtained in clinical studies or in preclinical studies will be indicative of results obtained in future clinical trials; whether Trimeris will be able to obtain regulatory approvals and such other factors as are set forth in the risk factors detailed from time to time in Trimeris' periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in Trimeris' Form 10-K filed with the Securities and Exchange Commission on March 13, 2009, which are incorporated herein by reference. The forward looking statements are made only as of the date of publication. Except as otherwise required by law, the Company specifically disclaims any obligation to update any of these forward looking statements.

Additional Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Trimeris. Arigene has filed a tender offer statement on Schedule TO, as amended, with the SEC and has mailed an offer to purchase, forms of letter of transmittal and related documents to Trimeris stockholders. Trimeris has filed with the SEC and mailed to Trimeris stockholders, a solicitation/recommendation statement on Schedule 14D-9, as amended. These documents contain important information about the tender offer and stockholders of Trimeris are urged to read them carefully in their entirety, as well as any amendments or supplements to these documents if and when they become available. These materials were sent free of charge to all stockholders of Trimeris. Investors and security holders are also able to obtain free copies of the tender offer statement, the tender offer solicitation/recommendation statement and other documents filed with the SEC by Arigene and Trimeris through the web site maintained by the SEC at www.sec.gov.

SOURCE Arigene Co., Ltd.


'/>"/>
SOURCE Arigene Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma-Aldrich Enters Distribution Agreement With Stemgent, Inc. to Offer Lentivirus-Based Gene Delivery Products for Regenerative Medicine and Stem Cell Research
2. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
3. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
4. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
5. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
6. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
7. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
8. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
9. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
10. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
(Date:4/27/2016)... 27, 2016 At the Sachs ... of a Phase 2 clinical study of its lead ... undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, ... Germany and France ... at the time of surgery. "Despite advances in cochlear ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... New York City based oral and ... This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali is ... Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery is ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip meals occasionally (which is ... was among the many new lifestyle diet tips offered by nutritionists Pam Bonney and ... of Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, ...
(Date:4/29/2016)... FL (PRWEB) , ... April 29, 2016 , ... ... will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter ... a century of churning cream into butter, Grassland Dairy Products, located in Greenwood, ...
Breaking Medicine News(10 mins):